×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SCYX – scynexis, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SCYX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/19
07:00 am
scyx
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
Low
Report
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
11/17
10:15 am
scyx
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
Low
Report
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
11/12
01:30 pm
scyx
SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/7
01:15 am
scyx
SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/5
04:20 pm
scyx
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/28
08:43 am
scyx
SCYNEXIS (NASDAQ:SCYX) had its price target lowered by analysts at Guggenheim from $4.00 to $3.00. They now have a "buy" rating on the stock.
Medium
Report
SCYNEXIS (NASDAQ:SCYX) had its price target lowered by analysts at Guggenheim from $4.00 to $3.00. They now have a "buy" rating on the stock.
10/25
01:31 am
scyx
SCYNEXIS (NASDAQ:SCYX) was upgraded by analysts at Wall Street Zen t
Low
Report
SCYNEXIS (NASDAQ:SCYX) was upgraded by analysts at Wall Street Zen t
10/15
08:00 am
scyx
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
Low
Report
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
Date
Time
Symbol
Headline
Impact
11/14
02:28 pm
scyx
Form SCHEDULE 13G/A SCYNEXIS INC Filed by: Avidity Partners Management LP
Low
Report
Form SCHEDULE 13G/A SCYNEXIS INC Filed by: Avidity Partners Management LP
11/12
01:10 pm
scyx
Form SCHEDULE 13G/A SCYNEXIS INC Filed by: KINGDON CAPITAL MANAGEMENT, L.L.C.
Low
Report
Form SCHEDULE 13G/A SCYNEXIS INC Filed by: KINGDON CAPITAL MANAGEMENT, L.L.C.
11/5
04:02 pm
scyx
Form 10-Q SCYNEXIS INC For: Sep 30
Medium
Report
Form 10-Q SCYNEXIS INC For: Sep 30
10/21
08:00 am
scyx
Form 4 SCYNEXIS INC For: Oct 17 Filed by: Angulo Gonzalez David
Low
Report
Form 4 SCYNEXIS INC For: Oct 17 Filed by: Angulo Gonzalez David
10/15
08:00 am
scyx
Form 8-K SCYNEXIS INC For: Oct 14
Low
Report
Form 8-K SCYNEXIS INC For: Oct 14
10/7
11:11 am
scyx
Form SCHEDULE 13G/A SCYNEXIS INC Filed by: FEDERATED HERMES, INC.
Low
Report
Form SCHEDULE 13G/A SCYNEXIS INC Filed by: FEDERATED HERMES, INC.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/8
SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
18.0%
4/13 Form 8-K SCYNEXIS INC For: Apr 10 13.1%
12/10 SCYNEXIS Announces Pricing of $35 Million Public Offering of Common Stock and Warrants 12.2%
9/18 SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC) 11.4%
11/12 SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update 9.1%
1/15 SCYNEXIS Inc (NASDAQ: SCYX) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 8.1%
5/1 Form S-3 SCYNEXIS INC 7.4%
4/24 Form 8-K SCYNEXIS INC For: Apr 21 7.3%
12/20 Form SC 13G SCYNEXIS INC Filed by: ARMISTICE CAPITAL, LLC 5.9%
2/18 SCYNEXIS Inc (NASDAQ: SCYX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%
4/13 Form 8-K SCYNEXIS INC For: Apr 10 13.1%
12/10 SCYNEXIS Announces Pricing of $35 Million Public Offering of Common Stock and Warrants 12.2%
9/18 SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC) 11.4%
11/12 SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update 9.1%
1/15 SCYNEXIS Inc (NASDAQ: SCYX) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 8.1%
5/1 Form S-3 SCYNEXIS INC 7.4%
4/24 Form 8-K SCYNEXIS INC For: Apr 21 7.3%
12/20 Form SC 13G SCYNEXIS INC Filed by: ARMISTICE CAPITAL, LLC 5.9%
2/18 SCYNEXIS Inc (NASDAQ: SCYX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%
TOP News Decliners
3/18
SCYNEXIS Inc (NASDAQ: SCYX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
-15.4%
7/24 SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study) -13.5%
4/21 SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection) -13.5%
11/14 SCYNEXIS Commends the CDC for the Recognition of Candida auris as a New "Urgent Threat" in its Updated Report on Antibiotic Resistance Threats in the United States -12.1%
12/9 SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants -11.8%
3/26 SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020 -11.5%
12/20 The CEO, President & Director of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Just Bought 32% More Shares [Yahoo! Finance News] -9.0%
12/11 Form 424B5 SCYNEXIS INC -7.8%
3/11 Form 10-K SCYNEXIS INC For: Dec 31 -7.2%
11/7 SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303) -7.0%
7/24 SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study) -13.5%
4/21 SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection) -13.5%
11/14 SCYNEXIS Commends the CDC for the Recognition of Candida auris as a New "Urgent Threat" in its Updated Report on Antibiotic Resistance Threats in the United States -12.1%
12/9 SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants -11.8%
3/26 SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020 -11.5%
12/20 The CEO, President & Director of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Just Bought 32% More Shares [Yahoo! Finance News] -9.0%
12/11 Form 424B5 SCYNEXIS INC -7.8%
3/11 Form 10-K SCYNEXIS INC For: Dec 31 -7.2%
11/7 SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303) -7.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: